Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Makenzi C. Evangelist

Hematology Oncology | Oncology | Hematology
New York Oncology Hematology PC
43 New Scotland Ave, 
Albany, NY 
Offers Telehealth
Advanced in WT1-Related Wilms Tumor Syndromes
New York Oncology Hematology PC
43 New Scotland Ave, 
Albany, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Makenzi Evangelist is a Hematologist Oncology specialist and an Oncologist in Albany, New York. Dr. Evangelist is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Non-Small Cell Lung Cancer (NSCLC).

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Samaritan Hospital Of Troy, New York
Albany Medical Center Hospital
St Peter's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

NEW YORK ONCOLOGY HEMATOLOGY PC
43 New Scotland Ave, Albany, NY 12208

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brigatinib, Alectinib
Study Phase: Phase 3
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

4 Total Publications

Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
Journal: Journal of the advanced practitioner in oncology
Published: January 13, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rahul Ravilla
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rahul Ravilla
Hematology Oncology | Hematology | Oncology

New York Oncology Hematology PC

43 New Scotland Ave, 
Albany, NY 
 (0.1 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rahul Ravilla is a Hematologist Oncology specialist and a Hematologist in Albany, New York. Dr. Ravilla is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Trevor J. Bayliss
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Trevor J. Bayliss
Hematology Oncology | Hematology | Oncology

Berkshire Faculty Services Inc

165 Tor Ct, 
Pittsfield, MA 
 (28.5 miles away)
413-447-2701
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Trevor Bayliss is a Hematologist Oncology specialist and a Hematologist in Pittsfield, Massachusetts. Dr. Bayliss is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Paget Disease of the Breast, and Colorectal Cancer. Dr. Bayliss is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David R. Shaffer
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David R. Shaffer
Oncology
43 New Scotland Ave, Mail Code 7, 
Albany, NY 
 (0.1 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances

David Shaffer is an Oncologist in Albany, New York. Dr. Shaffer is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Adult Soft Tissue Sarcoma, and Familial Prostate Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Evangelist's expertise for a condition
ConditionClose
    View All 50 Advanced Conditions
    View All 168 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile